Cytokinetics (CYTK)
NASDAQ:CYTK
Want to see CYTK full AI Analyst Report?
CYTK Stock Chart & Stats
$65.42
-$0.99(-2.05%)
At close: 4:00 PM EST
$65.42
-$0.99(-2.05%)
Day’s Range― - ―
52-Week Range$29.31 - $70.98
Previous CloseN/A
Volume107.14K
Average Volume (3M)1.90M
Market Cap
$8.05B
Enterprise Value$8.62B
Total Cash (Recent Filing)$882.22M
Total Debt (Recent Filing)$1.28B
Price to Earnings (P/E)―
Beta0.82
Next Earnings
Apr 30, 2026EPS Estimate
-1.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.50
Shares Outstanding123,162,800
10 Day Avg. Volume1,435,194
30 Day Avg. Volume1,895,025
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)-11.56
Price to Sales (P/S)86.62
P/FCF Ratio-14.26
Enterprise Value/Market Cap1.07
Enterprise Value/Revenue97.89
Enterprise Value/Gross Profit-439.10
Enterprise Value/Ebitda-12.29
Forecast
1Y Price Target
$93.47Price Target Upside42.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
EPS Forecast (FY)-6.5
Revenue Forecast (FY)$91.70M
Bulls Say, Bears Say
Bulls Say
Clinical Trial ReadoutA favorable Phase 3 ACACIA readout for aficamten could expand the drug's label into non-obstructive hypertrophic cardiomyopathy and materially increase the addressable market.
Commercial TractionRegulatory approvals for Myqorzo in multiple major markets and early certification of hundreds of prescribers support a faster commercial rollout and potential revenue growth.
Safety And Dosing ProfileAficamten's shorter half-life and optimized dosing strategy may reduce treatment interruptions and preserve efficacy signals, improving the odds of a clear positive trial outcome.
Bears Say
Financial And Dilution RiskRising share count, negative cash flow, and existing leverage could increase dilution risk and pressure earnings if clinical or commercial execution disappoints.
Market Access And CompetitionLimited payer coverage, a competitor's first‑mover advantage, and prescriber inertia could slow Myqorzo's market penetration despite demonstrated benefits.
Trial Design RiskHeterogeneous patient populations and a stringent statistical endpoint in the ACACIA trial could dilute treatment effects and make it harder to demonstrate a meaningful clinical benefit.
Cytokinetics News
CYTK FAQ
What was Cytokinetics’s price range in the past 12 months?
Cytokinetics lowest stock price was $29.31 and its highest was $70.98 in the past 12 months.
What is Cytokinetics’s market cap?
Cytokinetics’s market cap is $8.05B.
When is Cytokinetics’s upcoming earnings report date?
Cytokinetics’s upcoming earnings report date is Apr 30, 2026 which is in 12 days.
How were Cytokinetics’s earnings last quarter?
Cytokinetics released its earnings results on Feb 24, 2026. The company reported -$1.5 earnings per share for the quarter, beating the consensus estimate of -$1.564 by $0.064.
Is Cytokinetics overvalued?
According to Wall Street analysts Cytokinetics’s price is currently Undervalued.
Does Cytokinetics pay dividends?
Cytokinetics does not currently pay dividends.
What is Cytokinetics’s EPS estimate?
Cytokinetics’s EPS estimate is -1.65.
How many shares outstanding does Cytokinetics have?
Cytokinetics has 123,162,800 shares outstanding.
What happened to Cytokinetics’s price movement after its last earnings report?
Cytokinetics reported an EPS of -$1.5 in its last earnings report, beating expectations of -$1.564. Following the earnings report the stock price went down -10.285%.
Which hedge fund is a major shareholder of Cytokinetics?
Currently, no hedge funds are holding shares in CYTK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cytokinetics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$93.47 (42.88% Upside)
$93.47 (42.88% Upside)
Blogger Sentiment
Bullish
CYTK Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 102.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $9.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.4%
Last 30 Days ▼ 1.0%
Last 30 Days ▼ 1.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
67.10%
12-Months-Change
Fundamentals
Return on Equity
172.91%
Trailing 12-Months
Asset Growth
1.63%
Trailing 12-Months
Company Description
Cytokinetics
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
CYTK Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized material positive corporate milestones — regulatory approvals across major markets, immediate commercial readiness and early uptake indicators, large full-year revenue growth driven by collaboration milestones, and a strong cash balance — which collectively mark the company’s transition to a global commercial-stage biopharmaceutical company. Notwithstanding, costs have increased substantially as the company invests in commercial infrastructure and ongoing clinical programs, driving wider net losses and near-term uncertainty around product sales and ACACIA topline details. On balance, the strategic and operational positives (approvals, launch momentum, pipeline catalysts and strong cash runway) outweigh the financial short-term headwinds and information gaps, yielding a constructive but cautious outlook.View all CYTK earnings summariesCYTK Stock 12 Month Forecast
Average Price Target
$93.47
▲(42.88% Upside)
Technical Analysis
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Legend Biotech
―
Atrium Therapeutics, Inc.
―
Nuvalent
―
Ownership Overview
Currently, No data available
---